Non-formulary diclofenac potassium powder for oral solution (Cambia) will be covered on the prescription drug benefit when the following criteria for new therapy, stable or new member coverage are met:

- Prescribed for treatment of acute migraine by or in consultation with a headache specialist

-AND-

- Documented clinically significant intolerance, treatment failure* or contraindication to sumatriptan, rizatriptan and naratriptan.
  *Adequate trial for triptan requires use in at least 3 acute migraine attacks. If pain reduction occurs in 2 out of 3 episodes, the medication is considered effective.

-AND-

- Documented clinically significant intolerance, treatment failure or contraindication to acetaminophen

- Documented clinically significant intolerance, treatment failure or contraindication to four formulary NSAIDs (ibuprofen**, naproxen**, meloxicam, etodolac, nabumetone, indomethacin)

-AND-

- Documented clinically significant intolerance or treatment failure to diclofenac tablets (e.g. diclofenac sodium DR or 24hr SR) that would be expected to improve with powder formulation

-AND-

- Documented clinically significant intolerance or treatment failure to diclofenac capsule (e.g. Zorvolex) that would be expected to improve with powder formulation

-OR-

- Reorder only: Patient has previously met criteria and is already using the drug

** Over the counter liquid formulation available